Top of this page
Skip navigation, go straight to the content
Categories
-
Press Release: UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Nov 30, 2018
UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership -
UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook
Oct 30, 2018
UCB tracking well towards full year financial outlook -
Press Release: Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
Oct 23, 2018
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients -
Press Release: UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 23, 2018
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus -
Press Release: UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis
Oct 19, 2018
• Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA® (certolizumab pegol) in this patient population when added to common background medications -
Press Release: On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored
Oct 18, 2018
On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored -
Press Release: UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase
Oct 18, 2018
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase -
Press Release: FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters
Aug 13, 2018
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters -
Press Release: UCB Launches the Autoimmune Motherhood (AIM) Movement™ to Empower and Inform Women with Chronic Inflammatory Disease About Family Planning
Jul 11, 2018
The AIM Movement provides support, information and a place to share stories about motherhood in women with chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and Crohn’s disease (CD). -
Press Release: UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
May 29, 2018
• The U.S. Food and Drug Administration’s (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry of UCB into immuno-dermatology
• CIMZIA Phase 3 psoriasis studies demonstrated significant and clinically meaningful improvements in biologic-naïve patients and those previously treated with biologics, with clinical benefit maintained through 48 weeks and the flexibility of two dose regimens that allow for tailored treatment1